T. Rowe Price Associates
PMVP icon

T. Rowe Price Associates’s PMV Pharmaceuticals PMVP Stock Holding History

T. Rowe Price Associates’s Portfolio PMVP Stock Details PMVP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-33,600
Closed -$37K – 3129
2025
Q1 		$37K Hold
33,600
– – ﹤0.01% 2961
2024
Q4 		$51K Hold
33,600
– – ﹤0.01% 2940
2024
Q3 		$51K Hold
33,600
– – ﹤0.01% 2926
2024
Q2 		$55K Sell
33,600
-9,202
-21% -$16.6K ﹤0.01% 2843
2024
Q1 		$73K Buy
42,802
+17,858
+72% +$33.4K ﹤0.01% 2829
2023
Q4 		$78K Hold
24,944
– – ﹤0.01% 2748
2023
Q3 		$154K Buy
24,944
+983
+4% +$6.76K ﹤0.01% 2573
2023
Q2 		$150K Buy
23,961
+344
+1% +$1.8K ﹤0.01% 2607
2023
Q1 		$113K Buy
23,617
+5,278
+29% +$37.1K ﹤0.01% 2659
2022
Q4 		$160K Buy
18,339
+475
+3% +$5.06K ﹤0.01% 2597
2022
Q3 		$213K Buy
17,864
+2,251
+14% +$32.5K ﹤0.01% 2522
2022
Q2 		$222K Buy
15,613
+1,109
+8% +$16.1K ﹤0.01% 2561
2022
Q1 		$302K Sell
14,504
-36,720
-72% -$648K ﹤0.01% 2546
2021
Q4 		$1.18M Sell
51,224
-100,554
-66% -$2.43M ﹤0.01% 1942
2021
Q3 		$4.52M Buy
+151,778
New +$4.85M ﹤0.01% 1526
2021
Q2 		– Sell
-119,375
Closed -$3.93M – 2949
2021
Q1 		$3.93M Buy
+119,375
New +$4.71M ﹤0.01% 1523

Other funds holding PMVP

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
EC
Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

T. Rowe Price Associates's PMVP Position: Q2 2025 in Review

T. Rowe Price Associates sold out of PMV Pharmaceuticals (PMVP) in Q2 2025, closing a stake of 33,600 shares — an estimated $37K sold.

T. Rowe Price Associates first reported a position in PMVP in Q1 2021 and held it in 16 quarters. The position peaked at $4.52M in Q3 2021. 54 funds tracked by Wall St. Rank hold PMVP as of Q2 2025.

  • T. Rowe Price Associates reported no remaining PMV Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • T. Rowe Price Associates sold 33,600 PMV Pharmaceuticals shares in Q2 2025, an estimated $37K.
  • T. Rowe Price Associates first reported a position in PMV Pharmaceuticals in Q1 2021 and held it in 16 quarters.
  • T. Rowe Price Associates's PMV Pharmaceuticals position peaked at $4.52M in Q3 2021.
  • 54 funds tracked by Wall St. Rank held PMV Pharmaceuticals as of Q2 2025.

Based on T. Rowe Price Associates's 13F filing for Q2 2025, filed 14 Aug 2025.